anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Neural oscillations are proposed to be a mechanism of coordinating information processing across distributed regions of cortex. Different neural oscillations may correspond to different underlying neural computations. Noninvasive brain stimulation allows experimenters to modulate specific neural oscillations by targeting particular frequency bands. By collecting simultaneous electroencephalography (EEG), rhythmic transcranial magnetic stimulation (TMS) has been previously demonstrated to entrain neural oscillations at the frequency of stimulation. Furthermore, when the frequency of entrained neural oscillations is matched to the frequency of endogenous activity in a cognitive task, the brain stimulation improves behavioral performance. Therefore, noninvasive brain stimulation is a promising tool for improving cognition by inducing optimal neural activity via externally applied electromagnetic fields; e.g. cognitive control improvements.

Previous evidence has implicated neural activity in the alpha band (8-12 Hz) in information suppression and activity in the theta band (4-7 Hz) in information prioritization. Cognitive control task paradigms have been shown to elicit distinct activity in both of these bands. In this task, the stimuli are lateralized to the right and left visual field during encoding. After a short delay, a cue informs participants which stimuli (right or left) will be tested. Previous evidence found that alpha activity in parietal cortex is generated contralateral to irrelevant stimuli-supporting the role of alpha in information suppression-while theta activity in frontal cortex increases with the number of stimuli to be remembered-supporting the role of theta in information prioritization.

For the current study, the investigators propose to deliver rhythmic trains of TMS in either alpha frequency, theta frequency, or an arrhythmic control to modulate neural processing during a cognitive control task. By collecting simultaneous EEG with TMS, the investigators will be able to measure the entrained oscillations from rhythmic TMS. The goal of this experiment is to enhance the observed theta and alpha activity that is seen with the successful prioritization and suppression of information. To provide causal evidence that parietal cortex generates alpha activity and frontal cortex generates theta activity, the investigators will apply rhythmic TMS stimulation to two scalp locations: the anterior middle frontal gyrus and inferior intraparietal sulcus. By applying alpha frequency, theta frequency, and arrhythmic TMS at each location, the investigators will be able to examine the causal relationship of frontal theta oscillations in information prioritization and parietal alpha oscillations in information suppression.
Intervention: Chlorhexidine gel 7.1% topical 3 gm applied to the umbilical cord stump in one application. The community health worker is given the chlorhexidine to apply to the umbilical cord stump within 24 hours of delivery of the newborn infant.
Participants will insert one Dapivirine Vaginal Ring, 200 mg to be used continuously for 13 weeks. Participants will continue follow-up for an additional one to three days after final VR removal.
All participants will receive a standard-of-care therapy (rifafour e-275) tablet, orally, once daily from Day 1 to Day 14. Participants will receive the standard treatment for tuberculosis (i.e. rifafour e-275 or equivalent generic alternative) once the study treatment (Day 1 to Day 14) is completed.
The use of autograft is still the main method for reconstructing large defects of jaw bones. However, the spontaneous resorption of the graft bone is still severe, and hinders the success of dental implant(s) and chewing function even after microsurgical vascularization. But till now, there is no effective prevention method for this major problem. Based on previous studies, the investigators pioneered a simultaneous innervated vascularized iliac bone graft method, through neurorrhaphy between the nerves innervating iliac bone and recipient site. A clinical retrospective study showed that this new method significantly decreases postoperative osteoporosis, and ensures the success of dental implants (Refer to our published article Wang L\*, Wei J, Yang X, Yang Z, Sun M, Cheng X, Xu L, Lei D, Zhang C\*. Preventing early-stage graft bone resorption by simultaneous innervation: innervated iliac bone flap for mandibular reconstruction. PlastIc Reconstructive Surgery, 2017, 139(5):1152e-1161e, Cover Featured Article).

The investigators intend to randomly divide the vascularized iliac bone graft cases into traditional group without innervation and simultaneous innervation group (through neurorrhaphy between the nerves innervating iliac bone flap and recipient site). The efficacy of simultaneously innervated maxillofacial reconstruction for preventing graft bone resorption will be assessed using bone mineral density test of grafted bone, as a blinded method. The innervation and sensation of the internal oblique abdominis muscle island will be tested using neuroelectrophysiological examination. The recipient nerve having the best effect on preventing bone resorption, will be determined using hierarchical comparison method.
Childish games (10 minutes) Childlike games are used to help laugh without reason just like a child. The group is motivated by visualizing these games in their minds, raising the arms up in the form of a "Y" letter, and saying "very good (applause), very good (applause), hey" with palms facing the sky.
Patients will undergo tissue expansion. When the expanded flaps are harvested and transplanted, ICGA will be conducted intraoperatively. Meanwhile, the possible area of necrosis will be marked according to clinical experience. And then this area will be further divided into perfusion units (1\*1 square centimeter for each). The center of each perfusion unit will be marked as observation point, of which the fluorescence value will be recorded. After 1 week's follow-up postoperatively, the flap tissue will be determined by superimposing digital photography over ICGA imaging results, and the outcome of each observation point will be recorded. By analyzing the fluorescence value and outcome of each observation point, a cut-off point can be further identified to achieve both higher positive and negative predictive value, improving the utility and accuracy of ICGA in predicting the postoperative skin viability of expanded flaps.
A data collection and recommendation system collect data and a recommendation is generated. The information collected may be, for example, data from patients getting general blood tests. This information can include age, lifestyle, sex, and blood test results. A user accessing the system may receive a recommendation that is based on real user information. For example, a user with elevated cholesterol may be able to see that an additional 20 minutes of exercise, 4-5 days a week, could result, based on others in this same age range, in a reduction in total cholesterol of 15 points. Such a recommendation provides a user with concrete, real data that can be used to motivate and lead the user toward their goal. The system may be used not only for medical information, but in any area where data is collected and a recommendation made based on the data.
An apparatus for scanning and decoding barcodes includes an imager, a sample imaging area, and a processor. The imager is configured to capture images within a selectable field of view. The sample imaging area is configured to support a plurality of sample/tissue containers. Each sample/tissue container of the plurality of sample/tissue containers comprises a respective barcode. At least a portion of the plurality of sample/tissue containers are positioned within the field of view, such that a plurality of the respective barcodes is within the field of view. The processor is configured to receive captured images from the imager. The processor is configured to detect and decode each of the plurality of respective barcodes present in a first image of the captured images. The processor is also configured to define an associated region of interest for each barcode present in the first image.
On Day 1 of each 21-day cycle, patients will receive an intravenous (IV) infusion of Pertuzumab 840 mg loading dose followed by 420 mg per cycle, IV, D1, Q3W, in combination with trastuzumab 8 mg/kg loading dose followed by 6 mg/kg per cycle, IV, D1, Q3W and docetaxel 75 mg/m\^2. All subjects are required to receive study treatment as planned until investigator-assessed loss of benefit, toxic intolerance, withdrawal of consent, loss to follow-up, or death, whichever occurred first.
Patients receive triapine PO QD for 5 days prior to surgical resection. After surgical resection, patients receive temozolomide PO QD and triapine PO QD on days 1-5 of each cycle. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo MRI at screening and on study and undergo collection of blood samples on study.
Participants will receive MVC at the time of admission for transplantation and prior to transplant. Participants will receive MVC throughout their participation in the study, which will be 1 to 3 years depending on when they enroll.
A method of placing a dental implant analog in a physical model for use in creating a dental prosthesis is provided. The physical model, which is usually based on an impression of the patient's mouth or a scan of the patient's mouth, is prepared. The model is scanned. A three-dimensional computer model of the physical model is created and is used to develop the location of the dental implant. A robot then modifies the physical model to create an opening for the implant analog. The robot then places the implant analog within the opening at the location dictated by the three-dimensional computer model.
Haemangioma of the ribs is considered an extremely rare benign tumour. Here, we present a case of a young male with left tenth rib haemangioma vascularised by a costal artery giving the artery of Adamkiewicz presented as chronic cough. This was successfully treated through preoperative embolisation and surgical resection. A preoperative angiogram was performed to identify the origin of the artery of Adamkiewicz. The final diagnosis was confirmed histopathologically. There were no complications in the postoperative course and no recurrence during 12 months of follow-up.
Participants will receive transcutaneous tibial nerve stimulation for 30 minutes with a frequency of 12 Hz, pulse width of 300 microseconds, and to an intensity of the participant's tolerance under the motor threshold. This group will receive treatment two times per week.
The invention relates to a Chinese medicinal composition for treating cancerous pain, which is called as Aitongping for short. The Chinese medicinal composition is prepared from the following raw materials in portion by weight: 3 to 5 portions of drug armadillidium, 4 to 6 portions of pariphyllin, 3 to 5 portions of piper longum, 3 to 6 portions of prepared rhizoma typhonii, 1 to 3 portions of prepared frankincense, and 2 to 6 portions of prepared rhizoma arisaematis. The invention also provides a preparation method for the Aitongping. Pharmacology and medicament effect and clinical application prove that the Aitongping has good abirritation, improves the life quality of a cancerous person, has a good anticancer effect, and enhances nonspecific immunity function and cellular immune function remarkably. The remarkable clinical cure efficiency is 53 percent; and the total efficiency is 90 percent. The preparation has abundant medicinal sources, low cost, convenient medicament administration, no obvious toxic and side effect, and good development prospect.
The present invention relates to a composition containing a lipocalin 2 (LCN2) inhibitor as an active ingredient for preventing or treating inflammatory pain. According to the present invention, the amount of LCN2 protein expression is outstandingly increased in a condition of inflammatory pain. A mouse, which is treated with CFA and thus lack of a LCN2 gene, has: reduced reaction to a thermal or mechanical pain stimulus when compared to a normal mouse; neutrophils of which penetration into tissue is reduced; reduced expression of TNF-α, IL-1β, and IL-8; and significantly reduced activity of spinal microglia cells. Moreover, when a normal mouse is treated with recombinant LCN2 protein, the LCN2 protein increases sensitivity to a thermal or mechanical pain stimulus, penetration of nuetrophills into tissue, and expression of TNF-α, IL-1β, and IL-8. Consequently, the LCN2 protein significantly increases activity of spinal microglia cells. In addition, when an LCN inhibitor is applied to a model of an animal with inflammatory pain, an effect of alleviating inflammatory pain is provided. According to the present invention, the LCN2 inhibitor can be advantageously used for preventing or treating inflammatory pain.
Osseointegrated dental implants replace missing teeth and create an artificial surface for biofilms of complex microbial communities to grow. These biofilms on implants and dental surfaces can trigger infection and inflammation in the surrounding tissue. This study investigated the microbial characteristics of peri-implant mucositis (PM) and explored the correlation between microbial ecological imbalance, community function, and disease severity by comparing the submucosal microflora from PM with those of healthy inter-subject implants and intra-subject gingivitis (G) within a group of 32 individuals. We analyzed submucosal plaques from PM, healthy implant (HI), and G sites using metagenome shotgun sequencing. The bacterial diversity of HIs was higher than that of PM, according to the Simpson index. Beta diversity revealed differences in taxonomic and functional compositions across the groups. Linear discriminant analysis of the effect size identified 15 genera and 37 species as biomarkers that distinguished PM from HIs. Pathways involving cell motility and protein processing in the endoplasmic reticulum were upregulated in PM, while pathways related to the metabolism of cofactors and vitamins were downregulated. Microbial dysbiosis correlated positively with the severity of clinical inflammation measured by the sulcus bleeding index (SBI) in PM. Prevotella and protein processing in the endoplasmic reticulum also correlated positively with the SBI. Our study revealed PM's microbiological and functional traits and suggested the importance of certain functions in disease severity.IMPORTANCEPeri-implant mucositis is an early stage in the progression of peri-implantitis. The high prevalence of it has been a threat to the widespread use of implant prosthodontics. The link between the submucosal microbiome and peri-implant mucositis was demonstrated previously. Nevertheless, the taxonomic and functional composition of the peri-implant mucositis microbiome remains controversial. In this study, we comprehensively characterize the microbial signature of peri-implant mucositis and for the first time, we investigate the correlations between microbial dysbiosis, functional potential, and disease severity. With the help of metagenomic sequencing, we find the positive correlations between microbial dysbiosis, genus Prevotella, pathway of protein processing in the endoplasmic reticulum, and more severe mucosal bleeding in the peri-implant mucositis. Our studies offer insight into the pathogenesis of peri-implant mucositis by providing information on the relationships between community function and disease severity.
Non-vitamin K antagonist oral anticoagulants (NOACs) are generally recommended as 1st line therapy for oral anticoagulant in patients with atrial fibrillation (AF). But, the efficacy and safety of NOAC in AF patients with prosthetic mechanical heart valves or moderate to severe mitral valve stenosis have not been proven, and the guidelines recommend vitamin K antagonist (VKA) administration to those patient groups. This trial aims to compare the efficacy and safety of the edoxaban and the warfarin in AF patients with moderate to severe mitral valve stenosis.

Edoxaban in patients with aTrial fibrillation and MItral Stenosis (ERTEMIS) trial is a multicenter, randomized, open-label, investigator initiated phase 2 trial. The patients were randomly assigned to Edoxaban or Warfarin groups. The primary efficacy outcome is a composite of stroke and systemic arterial thromboembolism. The secondary efficacy outcomes are each component of the primary efficacy outcomes and death from any cause. The safety outcome was major bleeding.
PURPOSE: Little is known about the experience of healthcare professionals (HCPs) in the community providing healthcare to people with aphasia. In this study we aimed to explore the experiences of community HCPs in healthcare conversations with people with aphasia, and whether a high-tech, purpose-built aphasia app could assist.
METHODS: A generic qualitative study was conducted. HCPs from seven different clinical backgrounds were interviewed and data was thematically analysed.
RESULTS: The experiences of healthcare providers providing healthcare to people with aphasia were identified in six major themes. These were: (1) Healthcare communication topics; (2) HCP knowledge; (3) Communication exchanges during the interactions (4) Communication impacts on care; (5) Interactions and relationships grew easier over time; and (6) How technology could help interactions.
CONCLUSIONS: HCPs with more aphasia knowledge reported having more positive experiences. Unsuccessful interactions were believed to lead to negative emotional responses in people with aphasia and HCPs, and that miscommunications could lead to compromised care. HCPs reported that interactions and relationships with people with aphasia grew easier over time. HCPs need system level support to acquire the knowledge and skills needed to engage people with aphasia in effective healthcare conversations. Technology has potential to improve interactions.
An isolated polynucleotide encoding an influenza multi-epitope polypeptide, wherein the multi-epitope polypeptide comprises multiple copies of a plurality of influenza virus peptide epitopes wherein the polypeptide is B(X 1 ZX 2 Z . . . X m ) n B or B(X 1 ) n Z(X 2 ) n Z . . . (X m ) n B; wherein B is an optional sequence of 1-4 amino acid residues; n is at each occurrence independently an integer of 2-50; m is an integer of 3-15; each of X 1 , X 2  . . . X m  is an influenza peptide epitope of 4-24 amino acid residues; and Z at each occurrence is a bond or a spacer of 1-4 amino acid residues.
FIELD: immunology. SUBSTANCE: invention relates to method of determination, detection or quantitation in vitro of soluble cross-linked fibrin polymers Des AABB and cross-not-linked fibrin polymers Des AABB in sample obtained from mammal. Method involves contact of indicated sample with antibody or its immunoreactive fragments. Fragments do not bind specifically with: a) fibrinogen; b) fibrinogen catabolites; c) fibrin monomers Des AA, d; d) fibrin polymers Des AA; e) fibrin monomers Des AABB; f) cross-linked fibrinogen; g) complex fibrin monomer Des AA/fibrinogen and h) fibrin catabolites. Methods of estimation of predisposition to thrombotic state, confirmation of diagnosis of the presence of thrombotic state and monitoring of thrombotic state in mammal involve determination of amount of soluble cross-linked fibrin polymers Des AABB and soluble cross-not-linked fibrin polymers Des AABB in sample obtained from mammal. Invention proposes kits used for determination, detection or quantitation of soluble cross-linked fibrin polymers Des AABB and soluble cross-not-linked fibrin polymers Des AABB in sample, for estimation of predisposition to thrombotic state in mammal, for confirmation of diagnosis of thrombotic state and for determination of stage of thrombotic state in mammal. Invention provides to determine predisposition to thrombotic state in mammal reliably. EFFECT: improved method of immunoassay. 34 cl, 12 tbl
Fos-related antigen-2 (Fra-2) is the most recently discovered member of the Fos family and, by dimerizing with Jun proteins, forms the activator protein 1 (AP-1) transcription factor. By inducing or repressing the transcription of several target genes, Fra-2 is critically involved in the modulation of cell response to a variety of extracellular stimuli, stressors and intracellular changes. In physiological conditions, Fra-2 has been found to be ubiquitously expressed in human cells, regulating differentiation and homeostasis of bone, muscle, nervous, lymphoid and other tissues. While other AP-1 members, like Jun and Fos, are well characterized, studies of Fra-2 functions in cancer are still at an early stage. Due to the lack of a trans-activating domain, which is present in other Fos proteins, it has been suggested that Fra-2 might inhibit cell transformation, eventually exerting an anti-tumor effect. In human malignancies, however, Fra-2 activity is enhanced (or induced) by dysregulation of microRNAs, oncogenes and extracellular signaling, suggesting a multifaceted role. Therefore, Fra-2 can promote or prevent transformation, proliferation, migration, epithelial-mesenchymal transition, drug resistance and metastasis formation in a tumor- and context-dependent manner. Intriguingly, recent data reports that Fra-2 is also expressed in cancer associated cells, contributing to the intricate crosstalk between neoplastic and non-neoplastic cells, that leads to the evolution and remodeling of the tumor microenvironment. In this review we summarize three decades of research on Fra-2, focusing on its oncogenic and anti-oncogenic effects in tumor progression and dissemination.
Strong CYP3A4 Inhibitors

The coadministration with strong CYP3A inhibitors may increase dasatinib concentrations [see Clinical Pharmacology (12.3)]. Increased dasatinib concentrations may increase the risk of toxicity. Avoid concomitant use of strong CYP3A4 inhibitors. If concomitant administration of a strong CYP3A4 inhibitor cannot be avoided, consider a dasatinib dose reduction [see Dosage and Administration (2.5)]. 

Strong CYP3A4 Inducers

The coadministration of dasatinib with strong CYP3A inducers may decrease dasatinib concentrations [see Clinical Pharmacology (12.3)]. Decreased dasatinib concentrations may reduce efficacy. Consider alternative drugs with less enzyme induction potential. If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dasatinib dose increase. 

Gastric Acid Reducing Agents

The coadministration of dasatinib with a gastric acid reducing agent may decrease the concentrations of dasatinib. Decreased dasatinib concentrations may reduce efficacy. Do not administer H2 antagonists or proton pump inhibitors with dasatinib. Consider the use of antacids in place of H2 antagonists or proton pump inhibitors. Administer the antacid at least 2 hours prior to or 2 hours after the dose of dasatinib. Avoid simultaneous administration of dasatinib with antacids.
Abrasive silica particles for use in a dentifrice comprise, a first silica particles and a second silica particles. The first silica particles are present in at least 90 wt%, the second up to 10 wt%. The weight median particle diameter (d50) of the second particles is less than the first and from 15-70% of the d50 of the first. The first particles may have Relative Dentine Abrasion (RDA, aka Radioactive Dental Abrasion) between 30-110, a d50 <15µm, an oil absorption value <150g/100g, and a plastic abrasion value (PAV) from 2-8. The second particles may have RDA between 120-300, a d50 <9 µm, an oil absorption value <120g/100g, and a PAV from 7- 50. There may be a third silica particles present. The composition may have Ferric Tannate cleaning value FT100 from 40 to 100. Preparation comprises combining the particles. Useful as toothpaste for oral hygiene and cleaning teeth.